Natural History of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome

Abstract

The differential diagnosis of thrombotic microangiopathy (TMA) has become clearer following the establishment of the relationships between (1) diarrhea-associated hemolytic uremic syndrome (HUS) and Shiga toxin–producing Escherichia coli–HUS (STEC–HUS), (2) a markedly reduced ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) level and typical thrombotic thrombocytopenic purpura (TTP), and (3) abnormalities in the complement regulatory system and atypical HUS (aHUS). These TMAs include typical TTP, other forms of TMA, STEC–HUS, and aHUS. The pathological mechanisms of TMA still overlap among several forms of TMA. With respect to the management of TMA, the use of plasma exchange (PE) for typical TTP, additional steroid therapy for TMA and rituximab for typical TTP with a high titer of the inhibitor of ADAMTS-13, as well as eculizumab for aHUS, have also been established. Although several issues remain in the pathophysiology and management of TMA, new findings will hopefully resolve these problems in the near future.

Keywords

TTP - TMA - aHUS - STEC–HUS - ADAMTS-13

Note

All authors have no competing interests.

• References

• 1 Wehinger H, Zollinger HU, Schenck W, Künzer W. Hemolytic-uremic syndrome (Gasser). Report on 2 children with an uncommon disease course [in German]. Klin Wochenschr 1968; 46 (16) 874-881
• 2 Anagnou NP, Papanicolaou N, Fessas P. Recurrent attacks of hemolytic uremic syndrome. Haematologia (Budap) 1991; 24 (2) 101-105
• 3 Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014; 36 (4) 399-420
• 4 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347 (8) 589-600
• 5 George JN, Terrell DR, Swisher KK, Vesely SK. Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry. J Clin Apher 2008; 23 (4) 129-137
• 6 Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004; 41 (1) 68-74
• 7 Riedl M, Orth-Höller D, Würzner R. An update on the thrombotic microangiopathies hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). Semin Thromb Hemost 2014; 40 (4) 413-415
• 8 Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276 (44) 41059-41063
• 9 Gerritsen HE, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001; 98 (6) 1654-1661
• 10 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98 (6) 1662-1666
• 11 Soejima K, Mimura N, Hirashima M , et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem 2001; 130 (4) 475-480
• 12 Fujimura Y, Matsumoto M, Isonishi A , et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011; 9 (Suppl. 01) 283-301
• 13 Trachtman H, Austin C, Lewinski M, Stahl RA. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012; 8 (11) 658-669
• 14 Noris M, Caprioli J, Bresin E , et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5 (10) 1844-1859
• 15 George JN, Vesely SK, Terrell DR. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004; 41 (1) 60-67
• 16 Francis KK, Kalyanam N, Terrell DR , et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases. Oncologist 2007; 12: 11-19
• 17 Egan JA, Bandarenko N, Hay SN , et al. Differentiating thrombotic microangiopathies induced by severe hypertension from anemia and thrombocytopenia seen in thrombotic thrombocytopenia purpura. J Clin Apher 2004; 19 (3) 125-129
• 18 Wada H, Thachil J, Di Nisio M , et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; 11: 761-767
• 19 Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol 2000; 109 (3) 496-507
• 20 Török TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States—analysis of national mortality data, 1968-1991. Am J Hematol 1995; 50 (2) 84-90
• 21 Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 3 (7) 1432-1436
• 22 Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med 2010; 49 (1) 7-15
• 23 Ito-Habe N, Wada H, Matsumoto M , et al. A second national questionnaire survey of TMA. Int J Hematol 2010; 92 (1) 68-75
• 24 Rock GA, Shumak KH, Buskard NA , et al; Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325 (6) 393-397
• 25 Shumak KH, Rock GA, Nair RC ; Canadian Apheresis Group. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Ann Intern Med 1995; 122 (8) 569-572
• 26 Burns ER, Zucker-Franklin D. Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood 1982; 60 (4) 1030-1037
• 27 Siddiqui FA, Lian EC. Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma. J Clin Invest 1985; 76 (4) 1330-1337
• 28 Tsai HM. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. J Mol Med (Berl) 2002; 80 (10) 639-647
• 29 Neame PB. Immunologic and other factors in thrombotic thrombocytopenic purpura (TTP). Semin Thromb Hemost 1980; 6 (4) 416-429
• 30 Wu KK, Hall ER, Rossi EC, Papp AC. Serum prostacyclin binding defects in thrombotic thrombocytopenic purpura. J Clin Invest 1985; 75 (1) 168-174
• 31 Wagner DD. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb Haemost 1993; 70 (1) 105-110
• 32 Arya M, Anvari B, Romo GM , et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002; 99 (11) 3971-3977
• 33 Dong JF, Moake JL, Nolasco L , et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100 (12) 4033-4039
• 34 Moake JL, Rudy CK, Troll JH , et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307 (23) 1432-1435
• 35 Levy GG, Nichols WC, Lian EC , et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413 (6855) 488-494
• 36 Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A 1990; 87 (16) 6306-6310
• 37 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87 (10) 4235-4244
• 38 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87 (10) 4223-4234
• 39 Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci U S A 2004; 101 (29) 10578-10583
• 40 Upshaw Jr JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978; 298 (24) 1350-1352
• 41 Tsai H-M, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339 (22) 1585-1594
• 42 Furlan M, Robles R, Galbusera M , et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339 (22) 1578-1584
• 43 Ono T, Mimuro J, Madoiwa S , et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107 (2) 528-534
• 44 Fujimura Y, Matsumoto M, Kokame K , et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol 2009; 144 (5) 742-754
• 45 Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005; 106 (1) 11-17
• 46 Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91 (1) 1-19
• 47 Matsumoto M, Kokame K, Soejima K , et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2004; 103 (4) 1305-1310
• 48 Feys HB, Liu F, Dong N , et al. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost 2006; 4 (5) 955-962
• 49 Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001; 14 (2) 437-454
• 50 Veyradier A, Lavergne JM, Ribba AS , et al. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2004; 2 (3) 424-429
• 51 Johnson KK, Terrell DR, Lammle B , et al. Predicting risk for relapse in patients who have recovered from thrombotic thrombocytopenic purpura. Blood 2006; 108: 31 (Abstract 91)
• 52 Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 2001; 47 (7-8) 387-392
• 53 Ferrari S, Scheiflinger F, Rieger M , et al; French Clinical and Biological Network on Adult Thrombotic Microangiopathies. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109 (7) 2815-2822
• 54 Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103 (11) 4043-4049
• 55 Jacob S, Dunn BL, Qureshi ZP , et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012; 38 (8) 845-853
• 56 Nguyen TC, Liu A, Liu L , et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 2007; 92 (1) 121-124
• 57 Uemura M, Fujimura Y, Matsumoto M , et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99 (6) 1019-1029
• 58 Takahashi N, Wada H, Usui M , et al. Behavior of ADAMTS13 and Von Willebrand factor levels in patients after living donor liver transplantation. Thromb Res 2013; 131 (3) 225-229
• 59 Habe K, Wada H, Ito-Habe N , et al. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb Res 2012; 129 (5) 598-602
• 60 Mori Y, Wada H, Gabazza EC , et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002; 42: 572-580
• 61 Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365 (9464) 1073-1086
• 62 Mody RK, Luna-Gierke RE, Jones TF , et al. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli. Arch Pediatr Adolesc Med 2012; 166 (10) 902-909
• 63 Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; 1 (8325) 619-620
• 64 Ray PE, Liu XH. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol 2001; 16 (10) 823-839
• 65 Garg AX, Suri RS, Barrowman N , et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003; 290 (10) 1360-1370
• 66 Beutin L, Martin A. Outbreak of Shiga toxin-producing Escherichia coli (STEC) O104:H4 infection in Germany causes a paradigm shift with regard to human pathogenicity of STEC strains. J Food Prot 2012; 75 (2) 408-418
• 67 Kaplan BS, Meyers KE, Schulman SL. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 1998; 9 (6) 1126-1133
• 68 Besbas N, Karpman D, Landau D , et al; European Paediatric Research Group for HUS. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006; 70 (3) 423-431
• 69 Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361 (17) 1676-1687
• 70 Caprioli J, Noris M, Brioschi S , et al; International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108 (4) 1267-1279
• 71 Caprioli J, Castelletti F, Bucchioni S , et al; International Registry of Recurrent and Familial HUS/TTP. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003; 12 (24) 3385-3395
• 72 Heinen S, Sanchez-Corral P, Jackson MS , et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat 2006; 27 (3) 292-293
• 73 Noris M, Brioschi S, Caprioli J , et al; International Registry of Recurrent and Familial HUS/TTP. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362 (9395) 1542-1547
• 74 Kavanagh D, Richards A, Noris M , et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008; 45 (1) 95-105
• 75 Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J , et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007; 104 (1) 240-245
• 76 Frémeaux-Bacchi V, Miller EC, Liszewski MK , et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112 (13) 4948-4952
• 77 Delvaeye M, Noris M, De Vriese A , et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361 (4) 345-357
• 78 Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344 (14) 1058-1066
• 79 Hofer J, Giner T, Józsi M. Complement factor h-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment. Semin Thromb Hemost 2014; 40 (4) 431-443
• 80 Veyradier A, Obert B, Haddad E , et al. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatr 2003; 142 (3) 310-317
• 81 Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8 (11) 622-633
• 82 Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int 2006; 70 (1) 16-23
• 83 Turner N, Nolasco L, Nolasco J, Sartain S, Moake J. Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway. Semin Thromb Hemost 2014; 40 (5) 544-550
• 84 Scully M, Hunt BJ, Benjamin S , et al. British committee for standards in haematology: Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323-335
• 85 Sun L, Yu Z, Bu Y , et al. The clinical studies of 51 patients with thrombotic thrombocytopenic purpura. Zhonghua Xue Ye Xue Za Zhi 2014; 35 (2) 147-151
• 86 Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325 (6) 398-403
• 87 George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 2006; 21 (1) 49-56
• 88 Froissart A, Buffet M, Veyradier A , et al; French Thrombotic Microangiopathies Reference Center; Experience of the French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Crit Care Med 2012; 40 (1) 104-111
• 89 Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 53 (2) 259-272
• 90 Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 2013; 28 (11) 2097-2105
• 91 Würzner R, Riedl M, Rosales A, Orth-Höller D. Treatment of enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome (eHUS). Semin Thromb Hemost 2014; 40 (4) 508-516
• 92 Kielstein JT, Beutel G, Fleig S , et al; Collaborators of the DGfN STEC-HUS registry. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012; 27 (10) 3807-3815
• 93 Legendre CM, Licht C, Muus P , et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368 (23) 2169-2181
• 94 Cataland SR, Peyvandi F, Mannucci PM , et al. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol 2012; 87 (4) 430-432